Table 1. Other immunotherapeutic agents in development.
| Target | Name | Indication(s) | Company | Phase | Clinical Trials.gov identifier (selected trials) |
| B7.1 | Galiximab | Lymphoma | Biogen Idec | Phase II | NCT00516217 |
| B7H3 | MGA271 | Solid tumors | Macrogenics | Phase I | NCT01391143 |
| LAG3 | IMP321 | Solid tumors | Immuntep | Phase I/II | NCT00349934 |
| BMS-986016 | Solid tumors | Bristol-Myers Squibb | Phase I | NCT01968109 | |
| CD137 | BMS-663513 | Solid tumors | Bristol-Myers Squibb | Phase I/II | NCT00309023 |
| PF-05082566 | Lymphoma | Pfizer | Phase I | NCT01307267 | |
| KIR | IPH2101 | Myeloma, AML | Innate Pharma (BMS) | Phase II | NCT01248455 |
| NCT01256073 | |||||
| CCR4 | KW-0761 | ATL, CTCL | Kyowa Kirin | Phase I/II | NCT00920790 |
| CD27 | CDX-1127 | Solid tumors & Heme | CellDex Therapeutics | Phase I | NCT01460134 |
| Ox40 | MEDI-6469 | Solid tumors | MedImmune/AZ | Phase I | NCT02205333 |
| CD40 | CP-870,893 | Pancreatic | Genentech | Phase I | NCT01456585 |
Heme, hematologic tumors; ATL, acute T-cell leukemia; CTCL, cutaneous T-cell lymphoma; AML, acute myeloid leukemia.